Weekly Analysts' Ratings Updates for Regeneron Pharmaceuticals


They now have a "buy" rating on the stock. 11/27/2017 - Regeneron Pharmaceuticals was given a new $444.00 price target on by analysts at BMO Capital Markets.



from Biotech News